504305356 04/04/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4352037

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
RAQUALIA PHARMA INC.	03/16/2017

RECEIVING PARTY DATA

Name:	ASKAT INC.		
Street Address:	4-37-2 HIROJIHONMACHI SHOWA-KU		
City:	NAGOYA		
State/Country:	JAPAN		
Postal Code:	466-0841		

PROPERTY NUMBERS Total: 1

Property Type	Number	
Patent Number:	9447065	

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: wlp@wenderoth.com

Correspondent Name: WENDEROTH, LIND & PONACK, LLP

Address Line 1: 1030 15TH STREET, N.W.

Address Line 2: SUITE 400 EAST

Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER: R15F4390(US)	
NAME OF SUBMITTER: ANDREW B. FREISTEIN	
SIGNATURE: /Andrew B. Freistein/	
DATE SIGNED:	04/04/2017

Total Attachments: 4

source=4390 assignment#page1.tif source=4390 assignment#page2.tif source=4390 assignment#page3.tif source=4390 assignment#page4.tif

PATENT 504305356 REEL: 041845 FRAME: 0902

Deed of Assignment

Between **RaQualia Pharma Inc.**, a corporation of Japan, having a place of business at 8F Daiwa Meieki Bldg., 1-21-19 Meieki Minami Nakamura-ku, Nagoya, 450-0003, Japan (hereinafter referred to as ASSIGNOR)

AND **AskAt Inc.**, a corporation of Japan, having a place of business at 4-37-2 Hirojihonmachi Showa-ku, Nagoya, 466-0841, Japan (hereinafter referred to as ASSIGNEE)

WHEREAS the Assignor owns rights, titles and interests, in all countries of the world, in and to certain patents and patent applications identified in schedule 1 below ("Patents"); such schedule is incorporated herein by reference.

AND WHEREAS the Assignor has agreed to assign all its rights, titles and interests in the said Patents to the Assignee upon the terms herein set out.

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns to the Assignee as beneficial owner and free from all liens, charges, licenses and encumbrances or other third party rights, and the Assignee hereby accepts all of Assignor's entire rights, titles and interests in and to the Patents for all relevant states, including without limitation:

- (a) the Patents in each jurisdiction in which it was validated and all patent applications, patents and supplementary protection certificates which may derive or result from the same, including any divisionals, continuations, continuation-in-parts, reissues, extensions and registrations in relation to any thereof and all and any other rights in the inventions comprised in the above (together referred to as the "Patent Rights");
- (b) the benefit of all priority rights of the Patents;
- (c) the right to seek and obtain registrations in other countries in respect of the Patents or any other patent included in the Patent Rights;
- (d) the right to sue for and obtain injunctive relief, damages and all other relief in respect of any infringement or misuse (whether past, present or future) of the Patents or of the rights conferred by publication of the application for the same or of any other of the Patent Rights; and
- (e) any and all choses in action and any and all claims and demands, both at law and in equity, that said Assignor has or may have for damages or profits accrued or to accrue on account of the infringement of any of said Patents, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

1/4

The Assignor agrees to execute any further documents and do all things which the Assignee may require in order to vest or confirm the vesting in the Assignee (or the Assignee's successors in title or nominees as the case may be) of the Patents and all other Patent Rights in all relevant jurisdictions and all other property rights, titles and interests intended to be assigned, transferred or granted to the Assignee hereunder and to give the Assignee the full benefit of this Assignment including doing all acts which may be necessary or desirable to record the Patents in the name of the Assignee in all relevant jurisdictions. The Assignor hereby authorizes the Assignee and the Assignee's agents to sign all such forms on behalf of the Assignor as the Assignee considers appropriate in order to record the Patents and any other Patent Rights in the name of the Assignee. Assignor also agrees to transfer to Assignee all file histories for the Patents that are in Assignor or Assignor's agents' possession.

The parties hereto herby agree that the assignment contemplated hereby shall be deemed to be effective as of March (4), 2017 in accordance with the transactions contemplated by this Deed of Assignment between RaQualia Pharma Inc. and AskAt Inc. dated March (16), 2017.

Attachment: Schedule 1

IN WITNESS WHEREOF, Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below and Assignee has caused one of its representatives to hereunder set his hand on the date shown below to signify its acceptance of this Assignment.

Signed and witnessed this / / day of March 2017 at Aichi-ken, Japan

RaQualia Pharma Inc.

Name: Naoki TANI Title: President & CEO

Company Seal

y Scal

In the presence of:

(Witness 1)

Name: Kaoru SHIMADA Address: Aichi-ken, Japan In the presence of:

(Witness 2)

Name: Naomi KOBA Address: Aichi-ken, Japan

Accepted:

Signed and witnessed this 16th day of March 2017 at Aichi-ken, Japan

AskAt Inc.

By

Name: Akihiro FURUTA

Title: President

Company Seal

In the presence of:

(Witness 1)

Name: Yoshiyuki OKUMURA Address: Aichi-ken, Japan (Witness 2)

In the presence of:

Name: Takako OKUMURA Address: Aichi-ken, Japan

Schedule 1

List of Transfer Cases of RQ Ref. P0028BP (COX2_formulation) from RaQualia Pharma Inc. to AskAt Inc.

Title: PHARMACEUTICAL COMPOSITION

Country	Application No.	Patent No.	Office	Office Ref.
BR	BR 112014007568 9.	-	IWATANI	R15F4390(BR)
CA	2,852,618	-	IWATANI	R15F4390(CA)
CN	201280051358.6	-	IWATANI	R15F4390(CN)
HK	14109072.6	-	IWATANI	R15F4390(HK)C
EP	12841913.2	-	IWATANI	R15F4390(EP)
HK	14109215.4	-	IWATANI	R15F4390(HK)E
IN	641/MUMNP/2014	-	IWATANI	R15F4390(IN)
Љ	2013-539678	-	IWATANI	R15F4390JP
KR	10-2014-7011016	-	IWATANI	R15F4390(KR)
MX	MX/a/2014/004566	-	IWATANI	R15F4390(MX)
RU	2014119946	-	IWATANI	R15F4390(RU)
US	14/351,190	9447065	IWATANI	R15F4390(US)